---
document_datetime: 2025-10-20 12:27:00
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xeljanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xeljanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.1176943
conversion_datetime: 2025-12-29 20:25:29.886762
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xeljanz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber      | Scope                                | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|--------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | B.II.b.2.cReplacementor additionof a | 17/10/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000306831                     | manufacturer responsibleforimportation and/or batch release-B.I1.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     | PL   |                                                                                                                                                                                                                                                |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR/EMA/PSUR/0000248531              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2025 |     |      | Based on the PRAC review of data on safety and efficacy,thePRACconsidersthattherisk-benefit balance of medicinal products containing tofacitinib remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |
| Variation type IA / EMA/VR/0000263187 | This was an application for a group of variations. A.5Changeinthename and/or addressof a manufacturer/importer of the finished product(includingbatchrelease or quality controltestingsites)-A.5.bTheactivities for which the manufacturer/importer is responsible donotincludebatchrelease- Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer(including whererelevant quality control testing sites);or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive substance (where specified in the technical dossier)wherenoPh.Eur.Certificate of Suitabilityispartoftheapproveddossier;or | 03/04/2025 | N/A |      |                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| specified in the technical dossier) - Accepted   |
|--------------------------------------------------|